Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)
Primary resultResult — go to the resultDifference 16.5% 95% CI 3.4–28.8%Authors' conclusion
The ultra-short-acting beta-blocker landiolol was effective in reducing and maintaining HR without increasing vasopressor requirements after 24 h in patients with septic shock and persistent tachycardia. There were no differences in adverse events and clinical outcomes such as 28-day mortality vs. standard of care.
Study context
- Population
- Adults with septic shock and persistent tachycardia, 20 sites in 7 European countries, 2018–2022196 included
- Participants
- 99 vs 101
- Comparison
- Landiolol plus standard treatment vs standard treatment alone
- Landiololn = 99
- Controln = 101reference
- Primary endpoint
- Combined: HR response (HR 80-94 beats per minute) and its maintenance without increasing vasopressor requirements
- Follow-up
- First 24 h after treatment start
Methodological detailsopen-label, multicentre
- Open-label
- Multicentre
Primary result
As reported in the abstract
Difference
16.5%
95% CI 3.4–28.8%
P = 0.013
Events by treatment group
Landiolol vs Control
difference 16.5% (95% CI 3.4–28.8%); P = 0.013
Secondary outcomes
Tested secondary outcomes incl. 28-day mortality
- No statistically significant differences between groups
Safety
Adverse events
- No statistically significant differences between groups
Original publication
Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. Published 19 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →